Kill Criteria

Kill criteria emerged from the discipline of stage-gate project management developed by Robert G. Cooper in the 1980s. Cooper's research at McMaster University found that many organizations lacked formal mechanisms for stopping failing projects, resulting in massive resource waste. His Stage-Gate process introduced decision checkpoints where projects had to meet predefined criteria to advance, with explicit provisions for termination. The framework was widely adopted in product development.

The psychological foundation for kill criteria lies in well-documented cognitive biases. Escalation of commitment, closely related to the sunk-cost fallacy, causes decision-makers to continue investing in failing initiatives because of resources already spent rather than future prospects. Nobel laureate Daniel Kahneman's research on loss aversion shows that people experience losses roughly twice as intensely as equivalent gains, making project termination psychologically painful even when it is economically rational. Kill criteria counteract these biases by shifting the termination decision from a subjective judgment call to an objective assessment against predetermined standards.

In practice, effective kill criteria span multiple dimensions. Financial kill criteria might include failing to achieve a minimum return on investment by a specified date, exceeding budget by more than a defined percentage, or falling below revenue run-rate thresholds. Strategic kill criteria address shifts in market conditions, competitive dynamics, or organizational priorities that render the initiative's original rationale obsolete. Technical kill criteria specify performance benchmarks, quality standards, or feasibility milestones that the project must achieve. Intel's 1985 exit from memory chips shows the cost of not having them: by Andy Grove's own account, the company drifted for about a year before he asked Gordon Moore what a new CEO would do, and Moore answered that he would get out of memories. The exit freed resources for the microprocessor business that would define the company's future.

The pharmaceutical industry provides perhaps the most rigorous application of kill criteria. Drug development pipelines use clearly defined go/no-go criteria at each clinical trial phase. Major pharmaceutical companies set formal criteria for efficacy, safety, and commercial potential at each phase gate. This discipline is essential in an industry where only about 12% of drug candidates that enter clinical trials ultimately receive regulatory approval, according to the Tufts Center for the Study of Drug Development, which has estimated the cost of developing an approved drug, including failures and the cost of capital, at about $2.6 billion.

Implementing kill criteria requires establishing them at the outset of a project, before teams develop emotional attachment. The criteria must be specific, measurable, and agreed upon by all stakeholders. Critically, organizations must also create a culture where killing a project is treated as a responsible strategic decision rather than a failure. Alphabet's X, which has given bonuses to teams that end their own projects when the evidence turns against them, exemplifies this approach. Without cultural support, even well-defined kill criteria will be ignored, rationalized away, or quietly revised to keep struggling projects alive.